申联生物于2019年10月28日在上海证券交易所科创板上市，发行数量5,000万股，发行价格8.80元/股， 保荐机构（主承销商）为国信证券股份有限公司，保荐代表人为吴风来、王攀。 上市首日，申联生物盘中最高价报36.88元，为该股上市以来最高价。 中国经济网北京9月11日讯 申联生物(688098.SH)近日发布2025年半年度报告。报告期内，该公司实现营 业收入1.22亿元，同比下降3.68%；实现归属于上市公司股东的净利润-1286.97万元，上年同期 为-3450.80万元；实现归属于上市公司股东的扣除非经常性损益的净利润-1679.62万元，上年同期 为-3544.40万元；经营活动产生的现金流量净额为-3938.91万元，上年同期为-80.56万元。 2024年，申联生物实现营业收入30,341.47万元，同比增长0.64%；实现归属于上市公司股东的净利 润-4,474.01万元，上年同期为3,151.87万元；实现归属于上市公司股东的扣除非经常性损益的净利 润-4,837.65万元，上年同期为2,506.98万元；经营活动产生的现金流量净额为8,936.20万元，上年同期为 352.55万元。 ...

Core Viewpoint - The financial performance of Shenyuan Biological in 2024 shows a decline in net profit and a slight increase in revenue, indicating potential challenges ahead for the company. Financial Performance Summary - In 2024, the company achieved operating revenue of 30,341.47 million yuan, a year-on-year increase of 0.64% compared to 30,148.71 million yuan in 2023 [1][2] - The net profit attributable to shareholders was -4,474.01 million yuan, a significant decrease from the previous year's profit of 3,151.87 million yuan, representing a decline of 241.95% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -4,837.65 million yuan, down from 2,506.98 million yuan in the prior year, marking a decrease of 292.97% [1][2] - The net cash flow from operating activities was 8,936.20 million yuan, a substantial increase from 352.55 million yuan in the previous year, reflecting a growth of 2,434.71% [1][2] Q1 2025 Performance Summary - In the first quarter of 2025, the company reported operating revenue of 7,874.11 million yuan, a year-on-year decrease of 10.58% from 8,805.82 million yuan [3][4] - The net profit attributable to shareholders was -301.99 million yuan, compared to -220.92 million yuan in the same period last year [3][4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -445.01 million yuan, down from -286.93 million yuan in the previous year [3][4] - The net cash flow from operating activities was -2,856.10 million yuan, compared to -2,440.44 million yuan in the same period last year [3][4] Company Background - Shenyuan Biological was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2019, with an initial issuance of 50 million shares at a price of 8.80 yuan per share [4][5] - The highest stock price recorded was 36.88 yuan on the first trading day, but the stock is currently in a state of decline [4]